We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
105 hedge funds and large institutions have $73.1M invested in Lineage Cell Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
8,550% more call options, than puts
Call options by funds: $173K | Put options by funds: $2K
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
4% more funds holding
Funds holding: 101 → 105 (+4)
0.17% less ownership
Funds ownership: 38.31% → 38.14% (-0.17%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $103M → $73.1M (-$29.6M)
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
Holders
105
Holders Change
+4
Holders Change %
+3.96%
% of All Funds
1.81%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
16
Increased
17
Reduced
28
Closed
11
Calls
$173K
Puts
$2K
Net Calls
+$171K
Net Calls Change
-$80K
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$755K |
| 2 |
JP Morgan Chase
New York
|
-$305K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$224K |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$191K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$102K |
